Surmodics Buys Dx Substrate Developer BioFX in Deal Worth Up to $22.7M | GenomeWeb
NEW YORK (GenomeWeb News) - SurModics, a developer of drug-delivery and surface-modification technologies, said this week that it has acquired BioFX Laboratories in a deal worth up to $22.7 million.  
 
The agreement calls for SurModics to pay $11.3 million for BioFX, which makes substrates used by the in vitro diagnostics industry. SurModics said it could pay an additional $11.4 million on the achievement of certain revenue targets. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.